Synthetic lethality is explored with PARP inhibitors in several cancers such as ATM-deficient tumors from breast and ovaries, aggressive prostate cancers in combination with ATR inhibitors [243,244], and high-risk neuroblastomas under ATR inhibition [245]. The gene discussed is ATR; the disease is prostate cancer.